Revascularization Versus Medical Treatment in Patients With Ischemic Left Ventricular Dysfunction
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age19+
SponsorSamsung Medical Center
About this trial
Randomized trial to compare clinical outcomes between revascularization versus medical treatment alone in patients with ischemic cardiomyopathy and left ventricular dysfunction.
Eligibility criteria
Qualifiers
Subject must be at least 19 years of age
Patients with stage C heart failure and left ventricular ejection fraction<40%
Patients with significant coronary artery stenosis (diameter stenosis>50% with proven inducible myocardial ischemia by invasive physiologic assessment)
Coronary artery disease is amenable for percutaneous coronary intervention (PCI)
Disqualifiers
Myocardial infarction by universal definition within 4 weeks of randomization
Non-viable myocardium in myocardial viability test (cardiac magnetic resonance, dobutamine-stress echocardiography, delayed single-photon emission computerized tomography, or aneurysmal change in echocardiography)
Target lesions not amenable for PCI by operators' decision
Patients who need left ventricular assisted device (LVAD) or heart transplantation at the time of randomization
Trial design
Treatments tested in this trial
- Percutaneous coronary intervention
Treatment groups
900 Participants
are divided into 2 treatment groupsLocations
1Samsune Medical Center06351, Seoul South Korea
Sponsors and collaborators
Samsung Medical Center
Lead sponsor
Source ClinicalTrials.gov